Currently, breast cancer-targeted panel testing offered by clinical laboratories typically include up to 9 high and moderate penetrance breast cancer genes (ATM, BRCA1/2, CDH1, CHEK2, NBN, PALB2, PTEN, TP53) which would identify 85.7% of the mutation carriers seen in our study. This evidence concerns the gene TP53 and breast carcinoma.